Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration.

The study included healthy adult men, aged 25-45, who ingested one of three butyrate forms, with blood samples and ...

Announcing a new publication for Acta Materia Medica journal. The UPLC-QqQ-MS/MS method was established, validated, and used ...

Conclusion: The pharmacokinetics of imipenem in elderly patients were effectively characterized by the established PPK model, which includes creatinine clearance as a key covariate. This research will ...